mRNA Victoria

What mRNA Victoria does

mRNA Victoria is a Victorian state government initiative established in May 2021 as a division within the Department of Jobs, Skills, Industry and Regions (DJSIR). Its stated mandate is to position Victoria as the premier destination for mRNA research, manufacturing, clinical trials, and workforce training in the Asia-Pacific region through strategic investments and partnerships. The initiative does not build or sell commercial products; rather, it functions as an ecosystem coordinator and grant-making body, distributing public funds to researchers, biotech companies, and partner institutions. Melbourne is cited as the only city in the world to host both BioNTech and Moderna facilities, which the initiative uses as a structural anchor for its positioning.

Name

mRNA Victoria

Legal name

mRNA Victoria

Website

https://djsir.vic.gov.au

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

mRNA Victoria is a Victorian government initiative within DJSIR, established in 2021 to accelerate mRNA and RNA research and manufacturing. It disburses grant funding via mVRAF and mAP to biotechs, researchers, and 22 partner medical research institutes.

Ownership category

akta.pro rank

Product category

Government Biotechnology Grants

akta.pro primary industry

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

akta.pro secondary industries

RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), Plasmid DNA & mRNA Manufacturing Services (HLAAAKAE)

Keywords

• MRNA research funding
• Biotech industry development
• RNA vaccine manufacturing
• Government research grants
• Medical research partnerships

Headquarters

HQ city

Victoria

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Government Grant Funding: mRNA Victoria is a government initiative established in May 2021 that provides grant funding to support mRNA research and development. Since its inception, it has provided a total of $30.6 million to support 63 research projects through grant programs including the mRNA Victoria Research Acceleration Fund (mVRAF) and mRNA Victoria Activation Program (mAP).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

mRNA Victoria is a Victorian Government initiative that provides grant funding and partnership programs to accelerate mRNA and RNA-based research, development, translation, and manufacturing in Victoria. Through the mRNA Victoria Research Acceleration Fund (mVRAF) and mRNA Victoria Activation Program (mAP), the initiative has delivered $30.6 million across 63 research projects, while a Partnership Program links universities, research institutes, and global industry players to build a world-class mRNA ecosystem in the Asia-Pacific region.

Product overview

mRNA Victoria is a government initiative established in May 2021 to build a leading mRNA and RNA industry in the Asia Pacific region. The organization operates primarily through grant programs including the mRNA Victoria Research Acceleration Fund (mVRAF) and mRNA Victoria Activation Program (mAP), which together have provided $30.6 million to support 63 research projects. mRNA Victoria also operates a partnership program that collaborates with universities, research institutes, and industry globally to accelerate mRNA research, manufacturing, clinical trials, and workforce training.

Differentiator

Problem solved

Functional benefit

Products and services

• mRNA Victoria Research Acceleration Fund (mVRAF) Grant program that provides financial support to accelerate mRNA and RNA research projects in Victoria, helping researchers and biotech companies develop the next generation of mRNA vaccines and therapies.
• mRNA Victoria Activation Program (mAP) Grant program designed to support the development and activation of mRNA and RNA research initiatives, working with researchers and biotech companies to advance mRNA-based vaccines and therapies.
• mRNA Victoria Partnership Program Program that partners mRNA Victoria with universities, research institutes, and industry across the globe to accelerate mRNA research and manufacturing, building Victoria's position as the premier destination for mRNA research, manufacturing, clinical trials, and workforce training in the Asia-Pacific region.

Quantifiable outcome

• $30.6 million provided to 63 research projects

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• Victorian Universities and Research InstitutescoreStrategic or Co-development Partner · 1 May 2021mRNA Victoria partners with Victoria's 22 globally recognised medical research institutes to support the development of IP in key areas of need, creating a strong pipeline of RNA research candidates and an ecosystem to support manufacturing.
• Global Industry PartnerscoreStrategic or Co-development PartnermRNA Victoria partners with industry across the globe to accelerate mRNA research and manufacturing, building Victoria's position as the premier destination for mRNA research, manufacturing, clinical trials, and workforce training in the Asia-Pacific region.
• BioNTechcoreStrategic or Co-development PartnerMelbourne is the only city in the world to host both BioNTech and Moderna facilities, positioning Victoria as a global leader in mRNA technology.
• ModernacoreStrategic or Co-development PartnerMelbourne is the only city in the world to host both BioNTech and Moderna facilities, positioning Victoria as a global leader in mRNA technology.
• Department of Jobs, Skills, Industry and Regions (DJSIR)coreStrategic or Co-development PartnermRNA Victoria is a division within DJSIR, which supports breakthrough ideas and technologies to help solve problems and build the capability and confidence of Victorians to create, scale and invest in startups.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• BioNTech: BioNTech is a global mRNA therapeutics company that has established a manufacturing facility in Melbourne as part of mRNA Victoria's ecosystem. It is the most direct industry participant in the state's mRNA cluster and a core anchor tenant whose continued presence underpins the program's value proposition.
• CureVac: CureVac is a German mRNA therapeutics company developing vaccines and oncology therapies. It is a direct industry peer in the mRNA therapeutics category whose technology platform and pipeline direction are closely comparable to the research areas mRNA Victoria funds.
• MTPConnect: MTPConnect is an Australian Government Industry Growth Centre for the medical technologies, pharmaceuticals, and digital health sectors. It is a peer in mandate (national biotech ecosystem development, funding programs, sector coordination) but operates at the federal level rather than the state level.
• Moderna: Moderna is a global mRNA vaccines and therapeutics company with a manufacturing facility in Melbourne, making it the other half of the dual-anchor tenant structure that defines mRNA Victoria's positioning. Its regional footprint and supply chain relationships are central to the initiative's ecosystem strategy.
• California Institute for Regenerative Medicine (CIRM): CIRM is a state agency created by California voters to fund stem cell and related advanced therapy research through grants and infrastructure investments. It is directly comparable to mRNA Victoria as a state-funded grant-making body building a therapy-focused research and commercialization pipeline.
• Massachusetts Life Sciences Center: Massachusetts Life Sciences Center is a quasi-state agency that invests in life sciences research, workforce, and infrastructure to grow the state's biotech cluster. It is a structural analogue to mRNA Victoria as a state-level economic development body targeting life sciences ecosystem growth.

Broad incumbents

• CSIRO: CSIRO is Australia's national science agency and the country's largest research organization, with significant capability in health, biotech, and manufacturing. It is a broader incumbent that overlaps with mRNA Victoria's translational and manufacturing research ambitions at a national rather than state scope.
• A*STAR (Agency for Science, Technology and Research): A*STAR is Singapore's lead public-sector research agency, running major bioprocessing and biomedical research institutes. It is a broader incumbent in the same Asia-Pacific life sciences ecosystem where mRNA Victoria competes for talent, capital, and clinical trial activity.

Emerging players

• Arcturus Therapeutics: Arcturus Therapeutics is a clinical-stage mRNA medicines and gene editing company. It is an emerging peer in the mRNA therapeutics category with overlapping vaccine and rare disease programs, and is smaller in scale than the BioNTech/Moderna anchor tenants.

Others

• UK Bioindustry Association (BIA): The BIA is the UK trade association for the life sciences and biotech industry, representing companies, promoting sector investment, and coordinating with government. It is an adjacent ecosystem-building organization with a similar convening and policy-advocacy role, though operating as a member-funded industry body rather than a state agency.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/mrna-victoria

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about mRNA Victoria